Johnson & Johnson
4Q Revenues: $13.7 billion (+8.5%)
4Q Earnings: $2.2 billion (+3.5%)
FY Revenues: $53.3 billion (+5.6%)
FY Earnings: $11 billion (+10%)
Comments: Worldwide pharmaceutical sales were $23.3 billion for the year, up 4%. In the quarter, both domestic and international sales increased 4%. For the year, domestic sales were up 6% and international sales were up 11%. Sales growth reflects the strong performance of Risperdal, Remicade, Topamax, Velcade and Concerta. Earnings for the quarter include an after-tax charge for in-process R&D of $217 million associated with the acquisition of Pfizer Consumer Healthcare.